Related references
Note: Only part of the references are listed.Novel molecules targeting dyslipidemia and atherosclerosis
A. Tavridou et al.
CURRENT MEDICINAL CHEMISTRY (2008)
MicroRNAs as targets for antisense-based therapeutics
Jan Stenvang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
ISIS 301012 gene therapy for hypercholesterolemia: Sense, antisense, or nonsense?
Matthew K. Ito
ANNALS OF PHARMACOTHERAPY (2007)
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance
Cheol Soo Choi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Antisense apolipoprotein B therapy: where do we stand?
Fatima Akdim et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
The versatility of oligonucleotides as potential therapeutics
Fritz Eckstein
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
Rosie Z. Yu et al.
DRUG METABOLISM AND DISPOSITION (2007)
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
Irene F. Gazi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
Statins for non-alcoholic fatty liver disease: a new indication?
E. N. Liberopoulos et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Liver-specific inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice
Thomas A. Bell et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
Vasilios G. Athyros et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Modification of MyD88 mRNA splicing and inhibition of IL-1β signaling in cell culture and in mice with a 2′-β-methoxyethyl-modified oligonucleotide
Timothy A. Vickers et al.
JOURNAL OF IMMUNOLOGY (2006)
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
DB Savage et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302)
Tanya A. Watanabe et al.
OLIGONUCLEOTIDES (2006)
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice
XX Yu et al.
HEPATOLOGY (2005)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Antisense strategies
ST Crooke
CURRENT MOLECULAR MEDICINE (2004)
Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α
KL Sewell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
VG Athyros et al.
DIABETES CARE (2002)
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia
VG Athyros et al.
JOURNAL OF CARDIOVASCULAR RISK (2002)
Gene therapy for cardiovascular disease - A case for cautious optimism
R Khurana et al.
HYPERTENSION (2001)
Statin-fibrate combinations in patients with combined hyperlipidemia
VG Athyros et al.
ATHEROSCLEROSIS (2001)
Share Paper
